Zhongke Guosheng

Zhongke Guosheng is a Chinese biotech company developing functional bio-based new materials, with a focus on core products derived from 5-hydroxymethylfurfural (HMF) including 2,5-furandicarboxylic acid (FDCA) and 2,5-tetrahydrofurandimethanol (THFDM) . The company has also jointly established a JV named "Xinsheng Tai Materials" with AI drug discovery unicorn XtalPi . Its funding history spans from an angel round co-led by 5Y Capital and Matrix Partners China in 2021 , through a nearly RMB 100 million Pre-A round led by Legend Capital in 2022 , to a RMB 200 million A+ round in March 2025 co-led by CITIC Goldstone and Puhua Capital with continued follow-on from Legend Capital, 5Y Capital and Yuhang State Investment . The 2022-2023 Pre-A proceeds were directed toward scaling production capacity and developing downstream derivatives .